Share on StockTwits
 

Investment analysts at Argus raised their price objective on shares of Merck & Co (NYSE:MRK) from $54.00 to $62.00 in a note issued to investors on Wednesday, American Banking News reports. The firm currently has a “buy” rating on the stock. Argus’ target price suggests a potential upside of 15.87% from the company’s current price.

MRK has been the subject of a number of other recent research reports. Analysts at SunTrust upgraded shares of Merck & Co from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday. They now have a $62.00 price target on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Monday. Finally, analysts at Morgan Stanley upgraded shares of Merck & Co from an “equal weight” rating to an “overweight” rating in a research note to investors on Monday, January 27th. They now have a $60.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $54.89.

Merck & Co (NYSE:MRK) traded up 0.15% on Wednesday, hitting $53.59. 20,996,268 shares of the company’s stock traded hands. Merck & Co has a 1-year low of $40.83 and a 1-year high of $54.10. The stock has a 50-day moving average of $50.93 and a 200-day moving average of $48.53. The company has a market cap of $156.6 billion and a P/E ratio of 35.96.

Merck & Co (NYSE:MRK) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.88 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter in the prior year, the company posted $0.83 earnings per share. The company’s quarterly revenue was down 3.6% on a year-over-year basis. On average, analysts predict that Merck & Co will post $3.50 earnings per share for the current fiscal year.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.